Press Releases

Atomwise SAB, BOD 2021
Atomwise Adds Pharma Luminaries to Board of Directors and Scientific Advisory Board

Experts include Mike Varney, Bruce Roth, John Hamer, Kemal Malik, and Andrew Lo SAN FRANCISCO, Calif., June 17, 2021 – Atomwise has strengthened its drug discovery and development expertise by expanding its Board of Directors and creating a Scientific Advisory Board (SAB). These appointments signal a critical milestone for Atomwise as the company focuses on […]


June 17, 2021
Charles River Laboratories and Atomwise Form a Strategic Alliance to Provide Integrated, Artificial Intelligence-Driven Drug Discovery

Charles River reaffirms commitment to the future of drug discovery by advancing the Company’s integrated, innovative early-stage platform WILMINGTON, Mass., and SAN FRANCISCO, Calif., January 11, 2019 – Charles River Laboratories International, Inc. (NYSE: CRL) and Atomwise, Inc. today announced the formation of a strategic alliance that offers clients access to Atomwise’s artificial intelligence (AI)-powered, […]


January 11, 2019
Atomwise and Charles River Laboratories Form a Strategic Alliance to Provide Premier Artificial Intelligence-Powered Drug Discovery Capabilities

Charles River’s clients gain access to Atomwise’s Artificial Intelligence (AI) technology to improve novelty, quality and efficiency of preclinical drug discovery. SAN FRANCISCO, January 11, 2019 – Atomwise, Inc. today announced a strategic alliance with Charles River Laboratories International, Inc., which will offer biotech and pharmaceutical companies an end-to-end drug discovery solution that unites AI […]


January 11, 2019
Atomwise Enters into an Evaluation Agreement with Pfizer

Atomwise Inc., a leader in Artificial Intelligence (AI) for drug discovery and design, has entered into an evaluation agreement with Pfizer Inc. (NYSE: PFE). Pfizer will evaluate Atomwise’s platform to identify potential drug candidates for up to three target proteins selected by Pfizer. In the agreement, Pfizer will pay a technology access fee and additional […]


September 17, 2018
Atomwise Expands its Groundbreaking Artificial Intelligence Screening Program to Support Academic Projects Worldwide

Following a successful first year supporting 100 pioneering research projects, Atomwise opens a new round of awards to academic researchers. Atomwise Inc., a leader in using Artificial Intelligence (AI) for drug screening and design, has announced that 100 academic projects have received an Artificial Intelligence Molecular Screen (AIMS) Award in the first year of the […]


June 1, 2018
Atomwise Raises $45 Million Series A to Become the Preferred Artificial Intelligence Partner for the Global Pharmaceutical Industry

Atomwise Inc. today announced it has raised $45 million of growth funding, led by Monsanto Growth Ventures, DCVC (Data Collective), and B Capital Group, in support of its mission to become the preferred artificial intelligence partner for the world’s leading pharmaceutical, biotech, and agrochemical companies. Prior investors, including Y Combinator, Khosla Ventures, and DFJ participated […]


March 7, 2018
Monsanto and Atomwise Collaborate to Discover New Crop Protection Options Using Artificial Intelligence Technology

Monsanto Company and Atomwise have formed a unique research collaboration to increase the speed and probability of discovering and developing new crop protection products using artificial intelligence. “Each growing season, farmers around the world are challenged with yield-robbing pests and diseases, yet the average crop protection product takes up to 11 years and more than […]


June 14, 2017